PremiumPre-EarningsIs ITCI a Buy, Before Earnings? Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects Intra-Cellular reports Q4 EPS (16c), consensus (11c) PremiumThe FlySector Spotlight: Big Pharma will push to pause Medicare drug price negotiations Roth MKM biotech analyst holds an analyst/industry conference call Intra-Cellular downgraded to Neutral from Overweight at Piper Sandler PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald Intra-Cellular downgraded to Hold from Buy at Needham 
